Milos Stevic

Dr. Milos Stevic

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2017 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
VSVladan Sekulić
Vladan Sekulić
MRMilena Rajić
Milena Rajić
MVMarina Vlajković
Marina Vlajković
SISlobodan Ilić
Slobodan Ilić
MSMilos Stevic
Milos Stevic
MKMarko Kojić
Marko Kojić

1 December 2014 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
VZVesna Zivkovic
Vesna Zivkovic
MLMilica Lazovic
Milica Lazovic
ISIvona Stankovic
Ivona Stankovic
LDLidija Dimitrijevic
Lidija Dimitrijevic
MKMirjana Kocic
Mirjana Kocic
MHMarija Hrkovic
Marija Hrkovic

18 November 2015
Verified
Closed access
VSVladan Sekulic
Vladan Sekulic
MRM Rajic
M Rajic
VMVlajkovic Mž
Vlajkovic Mž
SISlobodan Ilic
Slobodan Ilic
MSMilos Stevic
Milos Stevic
MKM M Kojic
M M Kojic

26 November 2014 in Open Chemistry
Verified
Journal Article
Open access
PDF file
MVMarina Vlajković
Marina Vlajković
MRMilena Rajić
Milena Rajić
SISlobodan Ilić
Slobodan Ilić
MSMilos Stevic
Milos Stevic
MKMarko Kojić
Marko Kojić
MMMilovan Matović
Milovan Matović
The aim of this paper is to determine the influence of Ki-67 proliferation index on somatostatin receptor scintigraphy (SSRS) with Tc-99m-EDDA-HYNIC-TOC (Tc-99m-Tektrotyd) somatostatin analogue in patients with carcinoid tumors. Sixty-one patients (31 female, 30 male; age range: 33-76 years) were examined: 13 patients highly suspected of having a carcinoid, and 48 patients who had undergone the surgical removal of the tumor. Whole body SSRS at 4 h postinjection, spot scintigrams and SPECT of the selected regions were obtained for all patients. Tc-99m-Tektrotyd scintigraphy was classified as true positive in 26 out of 30 and true negative in 24 out of 28 patients. The sensitivity of Tc-99mTc-Tektrotyd scintigraphy was found to be as high as 94.74% in the group of patients with low mitotic index Ki67 (20%). The likelihood of Tc-99m-Tektrotyd scan being positive when a carcinoid is present was found to be inversely proportional to the value of Ki67 proliferation index. The results showed that Tc-99m-Tektrotyd SSRS is a sensitive method for diagnosing and staging patients with well-differentiated carcinoid tumors. However, in poorly differentiated tumors with high Ki67 proliferation index, additional analyses are necessary for precise staging.

1 January 2020
Verified
Closed access
MSMilos Stevic
Milos Stevic
MVMarina Vlajkovic
Marina Vlajkovic
FVFilip Velickovic
Filip Velickovic
GSGoran Stanojevic
Goran Stanojevic
MNMilica Nestorovic
Milica Nestorovic
FPFilip Petrovic
Filip Petrovic

1 December 2022 in AFMN Biomedicine
Verified
Journal Article
Open access
PDF file
FVFilip Veličković
Filip Veličković
MVMarina Vlajković
Marina Vlajković
MSMilos Stevic
Milos Stevic
NTNina Topić
Nina Topić
TATamara Anđelković
Tamara Anđelković
ĐMĐuro Macut
Đuro Macut
Neuroendocrine tumors (NETs) have increased expression of somatostatin receptors (SSTR), where subtype 2 and 5 are the most common. Overexpression of the SSTR is an outstanding molecular target for inoperable and metastatic NETs that enables a unique approach of targeted diagnosis and treatment. In addition to SSTRs, neuroendocrine tumors also express other receptors that can be suitable targets for visualization by nuclear medicine methods. This review paper is focused on the most common radiopharmaceuticals and their molecular targets that are used today based on theranostic approach in NETs. In conventional nuclear medicine, the most important diagnostic radiopharmaceuticals are somatostatin analogs (SSA) labeled with 111 In and 99m Tc, however 99m Tc has advantages over 111 In based on better physical characteristics and better performance. In recent years, highly potent theranostic pairs have been created for the imaging and treatment of NETs, which can strongly bind SSTR. Derivatives of 68 Ga-labeled octreotide are recommended for diagnostics and follow-up of NENs. The great advantage of 68 Ga radiopharmaceuticals is that identical compounds can be labeled with therapeutic radionuclides 90 Y and 177 Lu. Peptide receptor radionuclide therapy is a systemic molecular target therapy that has proven to be safe and very effective in controlling the disease and prolonging the survival of patients with advanced and inoperable NETs. With a negligible number of adverse events, this therapy is safe and should be administered to all patients who meet the necessary criterias, primarily overexpression of the somatostatin receptor type 2.